[{"data":1,"prerenderedAt":-1},["ShallowReactive",2],{"health-study-detail:100599676":3},{"organization":4,"armGroups":7,"interventions":14,"overallOfficials":20,"centralContacts":21,"locations":31,"responsibleParty":59,"collaborators":62,"id":64,"slug":65,"hasResults":66,"nctId":67,"briefTitle":68,"officialTitle":68,"acronym":69,"eligibilityCriteria":70,"healthyVolunteers":66,"sex":71,"minAge":72,"maxAge":73,"enrollmentInfo":74,"targetDuration":20,"studyType":77,"phases":78,"briefSummary":80,"conditions":81,"keywords":84,"overallStatus":34,"whyStopped":20,"lastUpdateSubmitDate":87,"lastUpdatePostDateStruct":88,"startDateStruct":91,"completionDateStruct":93,"leadSponsor":95,"locationsCount":96},{"fullName":5,"class":6},"The Cleveland Clinic","OTHER",[8],{"label":9,"type":10,"description":11,"interventionNames":12},"Alternating CPAP vs. No Treatment","EXPERIMENTAL","Each participant undergoes alternating 2-week periods of CPAP treatment and no treatment over approximately 13 weeks. This personalized intervention evaluates changes in AF burden and quality of life, with patients serving as their own controls.",[13],"Device: CPAP",[15],{"type":16,"name":17,"description":18,"armGroupLabels":19,"otherNames":20},"DEVICE","CPAP","CPAP will be randomized 2 weeks on 2 weeks off for 12 weeks total",[9],null,[22,27],{"name":23,"role":24,"phone":25,"phoneExt":20,"email":26},"Mina Chung, MD","CONTACT","2164442290","CHUNGM@ccf.org",{"name":28,"role":24,"phone":29,"phoneExt":20,"email":30},"Reena Mehra, MD","216-272-7405","mehrar@uw.edu",[32,46],{"facility":33,"status":34,"city":35,"state":36,"zip":37,"country":38,"countryCode":39,"cosmosGeoPoint":40,"geoPoint":45,"contacts":20},"Cleveland Clinic","RECRUITING","Cleveland","Ohio","44195","United States","US",{"type":41,"coordinates":42},"Point",[43,44],-81.69541,41.4995,{"lat":44,"lon":43},{"facility":47,"status":48,"city":49,"state":50,"zip":51,"country":38,"countryCode":39,"cosmosGeoPoint":52,"geoPoint":56,"contacts":57},"University of Washington","NOT_YET_RECRUITING","Seattle","Washington","98195",{"type":41,"coordinates":53},[54,55],-122.33207,47.60621,{"lat":55,"lon":54},[58],{"name":28,"role":24,"phone":29,"phoneExt":20,"email":30},{"type":60,"investigatorFullName":23,"investigatorTitle":61,"investigatorAffiliation":5,"oldNameTitle":20,"oldOrganization":20},"PRINCIPAL_INVESTIGATOR","Staff of Cardiovascular Medicine",[63],{"name":47,"class":6},"100599676","sleep-apnea-triggers-of-atrial-fibrillation-n-of-1-randomized-control-trial-sparta-100599676",false,"NCT07087587","Sleep Apnea Triggers of Atrial Fibrillation: N-of-1 Randomized Control Trial (SPARTA):","SPARTA","Inclusion Criteria:\n\n1. Informed consent\n2. Age 18-85 years\n3. High burden paroxysmal AF (≥1%)\n4. Moderate-severe OSA (AHI ≥ 15)\n5. Implanted device with atrial diagnostics\n6. Enrolled in remote monitoring\n\nExclusion Criteria:\n\n1. AF ablation \\\u003C6 months\n2. Valvular abnormalities\n3. Excessive daytime sleepiness in safety-critical jobs\n4. Plans for ablation during study\n5. Non-CPAP OSA treatment\n6. Recent device implantation (\\\u003C6 months)\n7. Central sleep apnea","ALL","18 Years","85 Years",{"count":75,"type":76},20,"ESTIMATED","INTERVENTIONAL",[79],"NA","A pilot N-of-1 randomized controlled trial evaluating the effectiveness of a personalized CPAP intervention in reducing atrial fibrillation (AF) burden and improving AF-related quality of life in patients with moderate to severe obstructive sleep apnea (OSA).",[82,83,17],"Afib","Sleep Apnea Syndrome, Obstructive",[85,17,86],"OSA","AFIB","2026-04-09",{"date":89,"type":90},"2026-04-13","ACTUAL",{"date":92,"type":90},"2025-08-25",{"date":94,"type":76},"2026-12-31",{"name":5,"class":6},2]